Next Article in Journal
New p-Substituted Salicylaldehyde Phenylhydrazone Derivatives: Synthesis, Characterization, and Antioxidant Activities
Previous Article in Journal
Synthesis and Anticancer Activity of New Thiopyrano[2,3-d]thiazoles Based on Cinnamic Acid Amides
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Validation of a Flow Cytometry Based Binding Assay for Evaluation of Monoclonal Antibody Recognizing EGF Receptor

by
Mercedes CEDEÑO-ARIAS
*,
Javier SÁNCHEZ-RAMÍREZ
,
Rancés BLANCO-SANTANA
and
Enrique RENGIFO-CALZADO
Center of Molecular Immunology, 216 St and 15 Ave. Atabey, Playa. POBox 16040, Havana 11600, Cuba
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2011, 79(3), 569-582; https://doi.org/10.3797/scipharm.1104-18
Submission received: 25 April 2011 / Accepted: 3 July 2011 / Published: 3 July 2011

Abstract

An ideal test used to characterize a product must be appropriate for the measurement of product quality, manufacturing consistency, product stability, and comparability studies. Flow cytometry has been successfully applied to the examination of antibodies and receptors on membrane surfaces; however, to date, the analytical validation of cytometry based assays is limited. Here we report on the validation of a flow cytometry-based assay used in the evaluation of nimotuzumab binding to cells over-expressing EGFR on cell surface. The assay was validated by examining, assay robustness, specificity, repeatability and intermediate precision. The assay was highly specific, robust for all studied factors except for cell fixation with 1% paraformaldehyde and met criteria for precision with RSD < 2%. In addition the assay has stability-indicating proper-ties evidenced by the ability to detect changes in mAb degraded samples. Most importantly, the assay demonstrated to be useful for its intended use.
Keywords: Binding Assays; Method validation; Monoclonal antibody; Nimotuzumab Binding Assays; Method validation; Monoclonal antibody; Nimotuzumab

Share and Cite

MDPI and ACS Style

CEDEÑO-ARIAS, M.; SÁNCHEZ-RAMÍREZ, J.; BLANCO-SANTANA, R.; RENGIFO-CALZADO, E. Validation of a Flow Cytometry Based Binding Assay for Evaluation of Monoclonal Antibody Recognizing EGF Receptor. Sci. Pharm. 2011, 79, 569-582. https://doi.org/10.3797/scipharm.1104-18

AMA Style

CEDEÑO-ARIAS M, SÁNCHEZ-RAMÍREZ J, BLANCO-SANTANA R, RENGIFO-CALZADO E. Validation of a Flow Cytometry Based Binding Assay for Evaluation of Monoclonal Antibody Recognizing EGF Receptor. Scientia Pharmaceutica. 2011; 79(3):569-582. https://doi.org/10.3797/scipharm.1104-18

Chicago/Turabian Style

CEDEÑO-ARIAS, Mercedes, Javier SÁNCHEZ-RAMÍREZ, Rancés BLANCO-SANTANA, and Enrique RENGIFO-CALZADO. 2011. "Validation of a Flow Cytometry Based Binding Assay for Evaluation of Monoclonal Antibody Recognizing EGF Receptor" Scientia Pharmaceutica 79, no. 3: 569-582. https://doi.org/10.3797/scipharm.1104-18

Article Metrics

Back to TopTop